Quarterly ResultAug 6, 2026, 07:03 AM
Insmed Q2 Revenue Jumps 296% to $425.5M; Net Loss Narrows to $13.2M
AI Summary
Insmed reported a substantial increase in product revenues for the second quarter and first half of 2026, primarily driven by the strong performance of BRINSUPRI following its recent approvals. The company's net loss significantly narrowed compared to the same periods last year, reflecting improved financial performance. These results highlight the successful commercialization efforts and pipeline advancements.
Key Highlights
- Q2 2026 product revenues reached $425.5 million, a 296% increase year-over-year.
- Net loss for Q2 2026 significantly narrowed to $13.2 million, down 96% from Q2 2025.
- Basic and diluted net loss per share for Q2 2026 was $0.06, an improvement from $1.70.
- Year-to-date 2026 product revenues were $731.5 million, up 265% from the prior year period.
- BRINSUPRI generated $309.2 million in Q2 2026 revenue, driven by recent approvals.
- ARIKAYCE contributed $116.3 million in Q2 2026 revenue.
- Cash and cash equivalents stood at $544.8 million as of June 30, 2026.
Price Impact
More from INSM